Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CX213
- Development stage
- Preclinical
- Lead developer
- Cenyx Biotech
- Modality
- Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
CX213 is a ceria-based nanoparticle (nanozyme) developed by Cenyx Biotech for the treatment of subarachnoid hemorrhage (SAH). It functions as a catalytic antioxidant by mimicking the activity of natural enzymes like superoxide dismutase and catalase. The mechanism of action involves the removal of reactive oxygen species (ROS) through a bidirectional electron exchange between Ce3+ and Ce4+ ions on the surface of the ceria nanoparticles. This catalytic cycle allows for the sustained neutralization of oxidative stress, which is a key driver of secondary brain injury following SAH. The drug is currently in preclinical development.
- Other names
- ceria-based nanoparticleceria nanozyme
Beyond the preview
Go deeper on CX213.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CX213.